Skip to main content
SpringerLink
Log in

Phenotypic Screening of iPSC-Derived Cardiomyocytes for Cardiotoxicity Testing and Therapeutic Target Discovery

  • Chapter
  • First Online:
Cardiovascular Regenerative Medicine

Abstract

The remarkable ability to generate unlimited numbers of cardiomyocytes and other differentiated cell types, from any person, and to edit the genome to introduce or correct disease-causing mutations, creates unprecedented opportunities for drug discovery. The new technologies have the potential to revolutionize the drug development pipeline, from delineating disease mechanisms and discovery of therapeutic targets to library screening and validation of therapeutic strategies. Moreover, since in vitro phenotypes reflect patient genetics and might predict outcomes, patient induced pluripotent stem cell (iPSCs) might eventually contribute to patient selection for clinical trials and inform individual patient treatment. This chapter focuses on the application of iPSC-derived cardiomyocytes in large-scale applications relevant to discovery of disease mechanisms and therapeutic targets for heart disease and for assessing the cardiomyopathic and proarrhythmic risk of drugs. We review the current status of large-scale screening of iPSC-derived cardiomyocyte disease models and explore new advances in cell culture, three-dimensional engineered tissues, and instrumentation that might address current weaknesses in the iPSC-cardiomyocyte technology. Our philosophy is that advancing iPSC-derived cardiomyocyte models that faithfully recapitulate disease and enable large-scale chemical or functional genomics screening could shift the paradigm of drug discovery by introducing human disease phenotype into the early stages of the development process, with the potential for increasing the safety and efficacy of new medicines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Harrison RK. Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 2016;15(12):817–8.

    Article  CAS  PubMed  Google Scholar 

  2. Wong CH, et al. Estimation of clinical trial success rates and related parameters. Biostatistics. 2018; https://doi.org/10.1093/biostatistics/kxx069.

    Article  PubMed Central  Google Scholar 

  3. Fordyce CB, et al. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol. 2015;65(15):1567–82.

    Article  PubMed  Google Scholar 

  4. MacDonald JS, et al. Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci. 2009;110(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  5. Waring MJ, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475–86.

    Article  CAS  PubMed  Google Scholar 

  6. Takahashi K, et al. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.

    Article  CAS  PubMed  Google Scholar 

  7. Lian X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013;8(1):162–75.

    Article  CAS  PubMed  Google Scholar 

  8. Burridge PW, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11(8):855–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. McKeithan WL, et al. An automated platform for assessment of congenital and drug-induced arrhythmia with hiPSC-derived cardiomyocytes. Front Physiol. 2017;8:766.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bedut S, et al. High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. Am J Physiol Heart Circ Physiol. 2016;311(1):H44–53.

    Article  PubMed  Google Scholar 

  11. Kolanowski TJ, et al. Making human cardiomyocytes up to date: Derivation, maturation state and perspectives. Int J Cardiol. 2017;241:379–86.

    Article  PubMed  Google Scholar 

  12. Yang X, et al. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014;114(3):511–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Koivumäki JT, et al. Structural immaturity of human iPSC-derived cardiomyocytes. Front Physiol. 2018;9:80.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kane C, et al. Excitation-contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes. Front Cell Dev Biol. 2015;3:59.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Dai DF, et al. Mitochondrial maturation in human pluripotent stem cell derived cardiomyocytes. Stem Cells Int. 2017;2017:5153625.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Malandraki-Miller S, et al. Changing metabolism in differentiating cardiac progenitor cells-can stem cells become metabolically flexible cardiomyocytes? Front Cardiovasc Med. 2018;5:119.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Knollmann BC. Induced pluripotent stem cell-derived cardiomyocytes: boutique science or valuable arrhythmia model? Circ Res. 2013;112(6):969–76. discussion 976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Keung W, et al. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2014;5(1):17.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Del Alamo JC, et al. High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta. 2016;1863(7 Pt B):1717–27.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Kim C, et al. Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells Dev. 2010;19(6):783–95.

    Article  CAS  PubMed  Google Scholar 

  21. Ma J, et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol. 2011;301(5):H2006–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Pekkanen-Mattila M, et al. The effect of human and mouse fibroblast feeder cells on cardiac differentiation of human pluripotent stem cells. Stem Cells Int. 2012;2012:875059.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Zhang Q, et al. Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res. 2011;21(4):579–87.

    Article  CAS  PubMed  Google Scholar 

  24. Lundy SD, et al. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013;22(14):1991–2002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ibrahim M, et al. The structure and function of cardiac t-tubules in health and disease. Proc Biol Sci. 2011;278(1719):2714–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dolnikov K, et al. Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells. 2006;24(2):236–45.

    Article  CAS  PubMed  Google Scholar 

  27. Poon E, et al. Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective. Mol Pharm. 2011;8(5):1495–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nikolaev VO, et al. Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res. 2006;99(10):1084–91.

    Article  CAS  PubMed  Google Scholar 

  29. Perry SJ, et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science. 2002;298(5594):834–6.

    Article  CAS  PubMed  Google Scholar 

  30. Jung G, et al. Time-dependent evolution of functional vs. remodeling signaling in iPSC-derived cardiomyocytes and induced maturation with biomechanical stimulation. FASEB J. 2016;30(4):1464–79.

    Article  CAS  PubMed  Google Scholar 

  31. Lyon AR, et al. Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proc Natl Acad Sci U S A. 2009;106(16):6854–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Nikolaev VO, et al. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 2010;327(5973):1653–7.

    Article  CAS  PubMed  Google Scholar 

  33. Kaumann A, et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation. 1999;99(1):65–72.

    Article  CAS  PubMed  Google Scholar 

  34. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem. 1998;273(30):18677–80.

    Article  CAS  PubMed  Google Scholar 

  35. Rapacciuolo A, et al. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem. 2003;278(37):35403–11.

    Article  CAS  PubMed  Google Scholar 

  36. Yang X, et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Parikh SS, et al. Thyroid and glucocorticoid hormones promote functional T-tubule development in human-induced pluripotent stem cell-derived cardiomyocytes. Circ Res. 2017;121(12):1323–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Hu D, et al. Metabolic maturation of human pluripotent stem cell-derived cardiomyocytes by inhibition of HIF1α and LDHA. Circ Res. 2018;123(9):1066–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ribeiro AJ, et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc Natl Acad Sci U S A. 2015;112(41):12705–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Jung G, et al. Time-dependent evolution of functional vs. remodeling signaling in induced pluripotent stem cell-derived cardiomyocytes and induced maturation with biomechanical stimulation. FASEB J. 2016;30(4):1464–79.

    Article  CAS  PubMed  Google Scholar 

  41. McBeath R, et al. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell. 2004;6(4):483–95.

    Article  CAS  PubMed  Google Scholar 

  42. Lutolf MP, et al. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 2005;23(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  43. Young JL, et al. Hydrogels with time-dependent material properties enhance cardiomyocyte differentiation in vitro. Biomaterials. 2011;32(4):1002–9.

    Article  CAS  PubMed  Google Scholar 

  44. Jacot JG, et al. Mechanobiology of cardiomyocyte development. J Biomech. 2010;43(1):93–8.

    Article  PubMed  Google Scholar 

  45. Young JL, et al. Mechanosensitive kinases regulate stiffness-induced cardiomyocyte maturation. Sci Rep. 2014;4:6425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ravi M, et al. 3D cell culture systems: advantages and applications. J Cell Physiol. 2015;230(1):16–26.

    Article  CAS  PubMed  Google Scholar 

  47. Lemoine MD, et al. Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density. Sci Rep. 2017;7(1):5464.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Fink C, et al. Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement. FASEB J. 2000;14(5):669–79.

    Article  CAS  PubMed  Google Scholar 

  49. Mathur A, et al. Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep. 2015;5:8883.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018;9:6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Ulmer BM, et al. Contractile work contributes to maturation of energy metabolism in hiPSC-derived cardiomyocytes. Stem Cell Reports. 2018;10(3):834–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ronaldson-Bouchard K, et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature. 2018;556(7700):239–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Hirt MN, et al. Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol. 2012;107(6):307.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Stevens KR, et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci U S A. 2009;106(39):16568–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Naito H, et al. Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation. 2006;114(1 Suppl):I72–8.

    PubMed  Google Scholar 

  56. Tulloch NL, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. 2011;109(1):47–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Giacomelli E, et al. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. Development. 2017;144(6):1008–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lemme M, et al. Atrial-like engineered heart tissue: an in vitro model of the human atrium. Stem Cell Reports. 2018;11:1378.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Mannhardt I, et al. Human engineered heart tissue: analysis of contractile force. Stem Cell Reports. 2016;7(1):29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Bielawski KS, et al. Real-time force and frequency analysis of engineered human heart tissue derived from induced pluripotent stem cells using magnetic sensing. Tissue Eng Part C Methods. 2016;22(10):932–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Thavandiran N, et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc Natl Acad Sci U S A. 2013;110(49):E4698–707.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Moretti A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363(15):1397–409.

    Article  CAS  PubMed  Google Scholar 

  63. Itzhaki I, et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol. 2012;60(11):990–1000.

    Article  CAS  PubMed  Google Scholar 

  64. Liang P, et al. Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome. J Am Coll Cardiol. 2016;68(19):2086–96.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Karakikes I, et al. Human-induced pluripotent stem cell models of inherited cardiomyopathies. Curr Opin Cardiol. 2014;29(3):214–9.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Birket MJ, et al. Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function. Cell Rep. 2015;13(4):733–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lan F, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12(1):101–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Han L, et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc Res. 2014;104(2):258–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Sun N, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4(130):130ra47.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Streckfuss-Bömeke K, et al. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes. J Mol Cell Cardiol. 2017;113:9–21.

    Article  PubMed  CAS  Google Scholar 

  71. Wyles SP, et al. Pharmacological modulation of calcium homeostasis in familial dilated cardiomyopathy: an in vitro analysis from an RBM20 patient-derived iPSC model. Clin Transl Sci. 2016;9(3):158–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Ma D, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34(15):1122–33.

    Article  CAS  PubMed  Google Scholar 

  73. Caspi O, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6(6):557–68.

    Article  CAS  PubMed  Google Scholar 

  74. Kim C, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;494(7435):105–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Seeger T, et al. A premature termination codon mutation of MYBPC3 causes hypertrophic cardiomyopathy via chronic activation of nonsense-mediated decay. Circulation. 2019;139:799–811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Stöhr A, et al. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J Mol Cell Cardiol. 2013;63:189–98.

    Article  PubMed  CAS  Google Scholar 

  77. Hinson JT, et al. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349(6251):982–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Cashman TJ, et al. Human engineered cardiac tissues created using induced pluripotent stem cells reveal functional characteristics of BRAF-mediated hypertrophic cardiomyopathy. PLoS One. 2016;11(1):e0146697.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Stillitano F, et al. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J. 2016;37(43):3282–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Hinson JT, et al. Integrative analysis of PRKAG2 cardiomyopathy iPS and microtissue models identifies AMPK as a regulator of metabolism, survival, and fibrosis. Cell Rep. 2017;19(11):2410.

    Article  CAS  PubMed  Google Scholar 

  81. Nakamura K, et al. iPS cell modeling of cardiometabolic diseases. J Cardiovasc Transl Res. 2013;6(1):46–53.

    Article  PubMed  Google Scholar 

  82. Tavian D, et al. Generation of induced Pluripotent Stem Cells as disease modelling of NLSDM. Mol Genet Metab. 2017;121(1):28–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wang G, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Drawnel FM, et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014;9(3):810–21.

    Article  CAS  PubMed  Google Scholar 

  85. Prathipati P, et al. Systems biology approaches to a rational drug discovery paradigm. Curr Top Med Chem. 2016;16(9):1009–25.

    Article  CAS  PubMed  Google Scholar 

  86. Moffat JG, et al. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat Rev Drug Discov. 2017;16(8):531–43.

    Article  CAS  PubMed  Google Scholar 

  87. Vincent F, et al. Developing predictive assays: the phenotypic screening “rule of 3”. Sci Transl Med. 2015;7(293):293ps15.

    Article  PubMed  CAS  Google Scholar 

  88. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Osherovich L. Hedging against academic risk. Science-Business eXchange. 2011;4(15):416.

    Article  Google Scholar 

  90. Prinz F, et al. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712.

    Article  CAS  PubMed  Google Scholar 

  91. Scannell JW, et al. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One. 2016;11(2):e0147215.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Nelson MR, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856–60.

    Article  CAS  PubMed  Google Scholar 

  93. Reddy AS, et al. Polypharmacology: drug discovery for the future. Expert Rev Clin Pharmacol. 2013;6(1):41–7.

    Article  CAS  PubMed  Google Scholar 

  94. Mullard A. New drugs cost US$2.6 billion to develop. Nat Rev Drug Discov. 2014;13:877.

    Google Scholar 

  95. Hoffmann P, et al. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods. 2006;53(2):87–105.

    Article  CAS  PubMed  Google Scholar 

  96. Redfern WS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58(1):32–45.

    Article  CAS  PubMed  Google Scholar 

  97. Sager PT, et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167(3):292–300.

    Article  PubMed  Google Scholar 

  98. Lawrence CL, et al. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods. 2005;52(1):46–59.

    Article  CAS  PubMed  Google Scholar 

  99. Kannankeril P, et al. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62(4):760–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Gintant G, et al. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15(7):457–71.

    Article  CAS  PubMed  Google Scholar 

  101. Andrejak M, et al. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis. 2013;106(5):333–9.

    Article  PubMed  Google Scholar 

  102. Pfeiffer ER, et al. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes. J Pharmacol Toxicol Methods. 2016;81:263–73.

    Article  CAS  PubMed  Google Scholar 

  103. Watanabe H, et al. Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes. J Toxicol Sci. 2017;42(4):519–27.

    Article  CAS  PubMed  Google Scholar 

  104. Millard D, et al. Cross-site reliability of human induced pluripotent stem cell-derived cardiomyocyte based safety assays using microelectrode arrays: results from a blinded CiPA Pilot Study. Toxicol Sci. 2018;164(2):550–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Blinova K, et al. International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep. 2018;24(13):3582–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Gilchrist KH, et al. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. Toxicol Appl Pharmacol. 2015;288(2):249–57.

    Article  CAS  PubMed  Google Scholar 

  107. Harris K, et al. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci. 2013;134(2):412–26.

    Article  CAS  PubMed  Google Scholar 

  108. Blinova K, et al. Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias. Toxicol Sci. 2017;155(1):234–47.

    Article  CAS  PubMed  Google Scholar 

  109. Ando H, et al. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods. 2017;84:111–27.

    Article  CAS  PubMed  Google Scholar 

  110. Yamazaki D, et al. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes. J Pharmacol Sci. 2018;136(4):249–56.

    Article  CAS  PubMed  Google Scholar 

  111. Qu Y, et al. Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the Maestro MEA Platform. Toxicol Sci. 2015;147(1):286–95.

    Article  CAS  PubMed  Google Scholar 

  112. Kitaguchi T, et al. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia – effects of 7 reference compounds at 10 facilities. J Pharmacol Toxicol Methods. 2016;78:93–102.

    Article  CAS  PubMed  Google Scholar 

  113. Kitaguchi T, et al. CSAHi study: detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J Pharmacol Toxicol Methods. 2017;85:73–81.

    Article  CAS  PubMed  Google Scholar 

  114. Nozaki Y, et al. CSAHi study: validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes – assessment of inter-facility and cells lot-to-lot-variability. Regul Toxicol Pharmacol. 2016;77:75–86.

    Article  CAS  PubMed  Google Scholar 

  115. Nozaki Y, et al. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: assessment of reference compounds and comparison with non-clinical studies and clinical information. Regul Toxicol Pharmacol. 2017;88:238–51.

    Article  CAS  PubMed  Google Scholar 

  116. Grimm FA, et al. High-content assay multiplexing for toxicity screening in induced pluripotent stem cell-derived cardiomyocytes and hepatocytes. Assay Drug Dev Technol. 2015;13(9):529–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Csöbönyeiová M, et al. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells. Can J Physiol Pharmacol. 2016;94(7):687–94.

    Article  PubMed  CAS  Google Scholar 

  118. Savalia S, et al. Cardiac arrhythmia classification by multi-layer perceptron and convolution neural networks. Bioengineering (Basel). 2018;5(2):35.

    Article  PubMed Central  Google Scholar 

  119. Andreotti F, et al. Comparing feature-based classifiers and convolutional neural networks to detect arrhythmia from short segments of ECG. Comput Cardiol. 2017;44:1–4.

    Google Scholar 

  120. Rajpurkar P, et al. Cardiologist-level arrhythmia detection with con-volutional neural networks. arXiv170701836. 2017. 2017.

    Google Scholar 

  121. Yeh ET, et al. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  CAS  PubMed  Google Scholar 

  122. Aleman BM, et al. Cardiovascular disease after cancer therapy. EJC Suppl. 2014;12(1):18–28.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Moslehi J, et al. Grounding cardio-oncology in basic and clinical science. Circulation. 2017;136(1):3–5.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Sharma A, et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017;9(377):eaaf2584.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Lamore SD, et al. Deconvoluting kinase inhibitor induced cardiotoxicity. Toxicol Sci. 2017;158(1):213–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Talbert DR, et al. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol Sci. 2015;143(1):147–55.

    Article  CAS  PubMed  Google Scholar 

  127. Moslehi JJ, et al. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33(35):4210–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Kawatou M, et al. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue. Nat Commun. 2017;8(1):1078.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Takeda M, et al. Development of in vitro drug-induced cardiotoxicity assay by using three-dimensional cardiac tissues derived from human induced pluripotent stem cells. Tissue Eng Part C Methods. 2018;24(1):56–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Amano Y, et al. Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration Layer-by-Layer technique and their application for pharmaceutical assays. Acta Biomater. 2016;33:110–21.

    Article  CAS  PubMed  Google Scholar 

  131. Lu HF, et al. Engineering a functional three-dimensional human cardiac tissue model for drug toxicity screening. Biofabrication. 2017;9(2):025011.

    Article  PubMed  CAS  Google Scholar 

  132. Huebsch N, et al. Miniaturized iPS-cell-derived cardiac muscles for physiologically relevant drug response analyses. Sci Rep. 2016;6:24726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Mannhardt I, et al. Blinded contractility analysis in hiPSC-cardiomyocytes in engineered heart tissue format: comparison with human atrial trabeculae. Toxicol Sci. 2017;158(1):164–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We gratefully acknowledge support from the National Institutes of Health (NIH) (R01HL130840. R01HL128072 and R21HL141019 to MM). TM acknowledges support from AHA (Undergraduate Summer Research Program). DAMF is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 708459.

Conflict of Interest Statement

The authors have no conflicting interests.

Author information

Authors and Affiliations

  1. Cardiovascular Institute and the Department of Medicine, Stanford University, Stanford, CA, USA

    Arne A. N. Bruyneel, Tyler Muser, Vaidya Parthasarathy, Dries Feyen & Mark Mercola

Authors
  1. Arne A. N. Bruyneel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tyler Muser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vaidya Parthasarathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dries Feyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark Mercola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Mercola .

Editor information

Editors and Affiliations

  1. Department of Biomedical Engineering, Emory University School of Medicine and Georgia Institute of Technology, Atlanta, GA, USA

    Vahid Serpooshan

  2. Cardiovascular Institute and Department of Medicine, Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA

    Sean M. Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bruyneel, A.A.N., Muser, T., Parthasarathy, V., Feyen, D., Mercola, M. (2019). Phenotypic Screening of iPSC-Derived Cardiomyocytes for Cardiotoxicity Testing and Therapeutic Target Discovery. In: Serpooshan, V., Wu, S. (eds) Cardiovascular Regenerative Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-20047-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-20047-3_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-20046-6

  • Online ISBN: 978-3-030-20047-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation